GILD34:BVMF
Gilead Sciences
65,81 R$
0,00%
(0,00) 1K
16-okt, 16:56:00 (GMT-3) · BRL
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoGILD34 tikeri uchun statistika yaratilmoqda...
Ochish
66,36 R$
Yuqori
66,41 R$
Past
65,81 R$
Bozor kapitali
193,67 mlrd
Oʻrtacha hajm
261,00
Hajmi
1,78 ming
52 haftalik eng yuqori
67,38 R$
52 haftalik eng past
51,33 R$
Muomaladagi aksiyalar
1,24 mlrd
Xodimlar soni
17 ming
Ochish
66,36 R$
Yuqori
66,41 R$
Past
65,81 R$
Bozor kapitali
193,67 mlrd
Oʻrtacha hajm
261,00
Hajmi
1,78 ming
52 haftalik eng yuqori
67,38 R$
52 haftalik eng past
51,33 R$
Muomaladagi aksiyalar
1,24 mlrd
Xodimlar soni
17 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
The Motley Fool
·
11 soat oldin
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
ad-hoc-news.de
·
13 soat oldin
Gilead Sciences stock trades 0.32 percent above its Xetra close
Simply Wall Street
·
1 kun oldin
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
MarketBeat
·
1 kun oldin
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences haqida
CEODaniel O'Day
Xodimlar soni17 ming
Asos solingan22-iyn, 1987
Bosh ofislarFoster City, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytgilead.com